Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Chad Gloetzner United States

Digital physician platform for over 2.5 million registered Chinese doctors. We also help US pharma, biotech and medical device companies strategize and promote products and services directly to Chinese physicians.
Website:
MedSci.cn
Year of foundation
2002
Looking for
Headquartner in China
Yes
MedSci Healthcare
SVP Sales 
Functionality
Management

John Gregg United States

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.
Website:
www.balinbac.com
Company Size (Fulltime employees)
11-50
Year of foundation
2014
Looking for
Funding Status
Seed investors. Finance through R&D collaborations prior to Series A round.
Headquartner in China
No
Plan in China
We have a drug and device platform. We want to partner with companies in Shenzhen for the device and CDMO/Drug Companies in other parts of China for manufacture of API and drug product for distribution in the market in China and Asia.
BALINBAC THERAPEUTICS, INC.
CEO 
Functionality
Management

Miao Guo United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.
VP, Marketing and Operations 

Henry han United States

EpicentRx is an immuno-oncology company whose focus is to identify and develop less toxic and more effective immunotherapy-based anti-cancer treatments that are active not only as single agents, but that also sensitize tumors to the cytotoxic effects of chemotherapy, radiation and immune checkpoint blockade. EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC. The company is also advancing multiple programs through its smart virus AdAPT platform, including three anti-SARS-CoV-2 vaccines, a TGF-beta "trap" starting Phase 1, and various personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors. For more information regarding EpicentRx, go to: http://www.epicentrx.com.
Website:
https://www.epicentrx.com
Looking for
Headquartner in China
No
Epicentrx
BD HEAD 
Functionality
Business Development

Wei Ji United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.
VP 

Lili Jiang United States

As China Focus conference organizer, MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese Pharma companies and investors. We offer marketing, strategy and execution support to help healthcare innovation to grow by taking advantage of China’s huge market potential. We help innovative companies with China-Landing services, and help them find reliable Chinese investors and partners. MyBioGate is committed to linking healthcare innovations in China and overseas. We share global healthcare innovation, entrepreneurship, investment trends, KOL opinions, important events and conferences, in-depth research and analysis, allowing Chinese medical and health companies and investors to gain insight into trends and seize investment opportunities. Our China Focus forums, Global Healthcare Innovation Competitions, and road shows to China provide innovative companies who intend to enter China market with platforms for exposure to potential investors and partners.

Website:
https://en.mybiogate.com/
Mybiogate Inc.
Business Manager 

Scott Kahn United States

Alykomed Global Solutions LLC (AGSL), based in New York, is a respected and established provider of strategic personalized corporate solutions to the Biopharma industry. Our clients embody a wide range of companies, from innovative startups to larger established, public companies. Our projects include global business development, financial, investment, and capital support, and scientific based endeavors, among others. We are committed to our clients’ long term success, optimized growth strategies, and profitability potential.

We proudly apply our deep scientific knowledge, and combine this with our strong corporate and business development experience and an extensive scientific/business network. Our established and trusted financial investment banking service/registered broker partner, provides our clients with targeted capital and financial solutions and extensive access to institutional and retail investors. These capital services cover a wide range of investment opportunities and offerings, including, but not limited to IPOs and securities offerings, private placements, mergers and acquisition, bank and debt financing etc.

We also undertake strategic growth initiatives through global business development, researching scientific and drug development platforms, assisting with internal valuations, or assistance with other projects- we offer knowledge, experience, leadership, global awareness, and creativity. We work with a global network of professionals, having done business in North America, UK/Europe, and Asia, especially within the United States, Japan, South Korea, and China.
Website:
www.alykomedglobal.com
Looking for
Headquartner in China
No
Plan in China
Our current objectives are two-fold- *Meeting with companies that would benefit from our strategic consulting and financing services. *Meeting with investors and business development executives on behalf of current clients- -Company 1: Pre-clinical- Non-opioid, small molecules for neuropathic pain and epilepsy. Safety profiles and efficacy results better or equal to Pregabalin. -Company 2: Pre-clinical- Sepsis drug which, when co-administered with low dose corticosteroids dramatically improves survival. Seeking to fast track for COVID-19. -Company 3: Entering Phase II trials- ATP enhancing drugs for CNS indications, Mitochondrial Disease, Parkinson's, COVID-19 -Company 4.: Japan-based: Clinical telemedicine services for Japanese expats living overseas
Alykomed Global Solutions LLC
Founder 
Functionality
Management

Dorothy Ko United States

There is a high unmet need for central nervous system (CNS) diseases in the growing aging population. Genervon is bringing GM6, a new clinical-stage drug asset, to regulatory approval and commercialization in China for CNS diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Multiple Sclerosis (MS), and other neurodegenerative diseases. Most clinical trials for drugs developed through the traditional single-target drug approach have failed to treat the complex neurological disorders that involve multiple interrelated pathways. GM6 is neither an antibody nor a single-target agonist or antagonist. It is a pleiotropic regulator which simultaneously regulates multiple pathological pathways. Genervon has validated GM6’s target engagement of multiple targets and druggability. GM6 has been de-risked for toxicity in animal studies and safety in three clinical trials. IND documents filed with the FDA can be used to support regulatory filing in China for clinical trials. Genervon is interested to partner through licensing or merger and acquisition. 
Genervon Biopharmaceuticals discovered an endogenous embryonic-stage regulator, Motoneuronotrophic Factor (MNTF), and developed from it the pleiotropic drug GM6. Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases related to aging. GM6 simultaneously modulates multiple biological mechanisms (MOA) in the CNS and immune system to increase neurogenesis and lower inflammation. The MOAs include oxidative Stress, protein aggregation, kinase dysfunction, cholinergic signaling, extracellular matrix stability, and intrinsic apoptosis. GM6 reduces Beta Amyloid and phosphorylated tau in AD, reduces SOD1 in ALS, and reduces inflammation in animal models. GM6 passes through the blood-brain barrier and has good drug-like properties. GM6 has been studied in a Phase 1 and two Phase 2A trials and was shown to be safe and tolerable with positive clinical outcomes and favorable shifts in biomarkers SOD1, Tau and TDP43 in patients. A complete CMC package is ready for technology transfer.
Website:
www.genervon.com
Company Size (Fulltime employees)
1-10
Looking for
Please specify your partnering goal
Genervon is interested to partner through out-licensing or merger and acquisition.
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
GM6|pleiotropic regulator|ALS|Phase 2/3|USA, China, multiple EP, Japan, CA, Au
Assets Information 2
GM6|pleiotropic regulator|PD, MS, AD|Phase 2|USA, China, multiple EP, Japan, CA, Au
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 2.01MB)
Dorothy Ko
Genervon Biopharmaceuticals
Chief Operating Officer 
Functionality
Management

Alexander Lai United States

Bio-Tech
Website:
https://vincogen.com/
Looking for
Please specify your partnering goal
We're just looking for potential partners.
Headquartner in China
No
Vincogen
Business Development & Innovation Manager 

Gordon Lee United States

Dawn Biopharmaceuticals Inc (DBI) is a US firm founded by Gordon Lee, MD (UK MBChB), MBA (Wharton) who has access to a proprietary cell-based immunotherapeutic product for clinical development in the US. The product is a multivalent cancer therapy that integrates multiple anti-cancer mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses a therapeutic cytokine in the cancer - but not systemically.

(Please note that the website is pending.)

Website:
dawnbio.net
Company Size (Fulltime employees)
1-10
Year of foundation
2020
Looking for
Please specify your partnering goal
Strategic pharmaceutical or capital partner to accompany into Pre-IND and clinical trials.
Funding Status
Initial round
Headquartner in China
No
Plan in China
Open to partnerships with Chinese firms that have a proprietary small molecule or biodrug that could be encoded into our platform with the benefits of wider scope of applications, tumor-centric molecular therapeutic delivery, avoidance of peripheral (extra tumoral) actions and effects, and vectoring of high payload(s) for multi-arming.
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Dawn Biopharmaceuticals Inc.
Founder 
Functionality
Management